KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Shares Outstanding (Weighted Average) (2016 - 2026)

Emergent BioSolutions has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $51.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) fell 4.6% year-over-year to $51.9 million; the TTM value through Mar 2026 reached $51.9 million, down 4.6%, while the annual FY2025 figure was $53.5 million, 0.94% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $51.9 million at Emergent BioSolutions, down from $53.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $54.4 million in Q1 2025 and troughed at $50.0 million in Q2 2022.
  • A 5-year average of $52.0 million and a median of $51.9 million in 2026 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 6.72% in 2022 and later increased 4.21% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $50.1 million in 2022, then rose by 2.2% to $51.2 million in 2023, then rose by 3.52% to $53.0 million in 2024, then grew by 0.94% to $53.5 million in 2025, then dropped by 2.99% to $51.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for EBS at $51.9 million in Q1 2026, $53.5 million in Q4 2025, and $53.9 million in Q3 2025.